323 related articles for article (PubMed ID: 22359804)
1. Exceptions or alternatives to labeling requirements for products held by the Strategic National Stockpile. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2012 Feb; 77(24):5696-9. PubMed ID: 22359804
[TBL] [Abstract][Full Text] [Related]
2. Natural rubber-containing medical devices; user labelling--FDA. Final rule; interpretation.
Fed Regist; 1998 May; 63(87):24934-5. PubMed ID: 10179326
[TBL] [Abstract][Full Text] [Related]
3. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
[TBL] [Abstract][Full Text] [Related]
4. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
[TBL] [Abstract][Full Text] [Related]
5. TRICARE; off-label uses of devices; partial list of examples of unproven drugs, devices, medical treatments or procedures. Final rule.
Office of the Secretary, Department of Defense (DoD)
Fed Regist; 2012 Jun; 77(124):38177-8. PubMed ID: 22737762
[TBL] [Abstract][Full Text] [Related]
6. Registration of food facilities under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2005 Oct; 70(190):57505-9. PubMed ID: 16200686
[TBL] [Abstract][Full Text] [Related]
7. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
[TBL] [Abstract][Full Text] [Related]
8. Amendment of regulations regarding certain label statements on prescription drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 Feb; 67(22):4904-7. PubMed ID: 11829025
[TBL] [Abstract][Full Text] [Related]
9. Amended economic impact analysis of final rule requiring use of labeling on natural rubber containing devices--FDA. Final rule; amended economic analysis statement.
Fed Regist; 1998 Jun; 63(104):29552-90. PubMed ID: 10179863
[TBL] [Abstract][Full Text] [Related]
10. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 May; 67(90):31123-5. PubMed ID: 12001971
[TBL] [Abstract][Full Text] [Related]
11. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
12. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
[TBL] [Abstract][Full Text] [Related]
13. Medical devices; exception from general requirements for informed consent. Interim final rule.
Food and Drug Administration, HHS
Fed Regist; 2006 Jun; 71(109):32827-34. PubMed ID: 16795934
[TBL] [Abstract][Full Text] [Related]
14. Sunscreen drug products for over-the-counter human use; final monograph. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 May; 64(98):27666-93. PubMed ID: 10558542
[TBL] [Abstract][Full Text] [Related]
15. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
[TBL] [Abstract][Full Text] [Related]
16. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; amendment of final monograph for OTC antitussive drug products. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Aug; 65(148):46864-8. PubMed ID: 11067707
[TBL] [Abstract][Full Text] [Related]
17. Use of Symbols in Labeling. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2016 Jun; 81(115):38911-31. PubMed ID: 27311137
[TBL] [Abstract][Full Text] [Related]
18. Labeling and effectiveness testing; sunscreen drug products for over-the-counter human use; delay of compliance dates. Final rule; delay of compliance dates; request for comments.
Food and Drug Administration, HHS
Fed Regist; 2012 May; 77(92):27591-3. PubMed ID: 22606729
[TBL] [Abstract][Full Text] [Related]
19. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
[TBL] [Abstract][Full Text] [Related]
20. FDA regulatory compliance reconsidered.
Tobias C
Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
[No Abstract] [Full Text] [Related]
[Next] [New Search]
